RespiSure ER Bac Plus
Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin, chemically inactivated and adjuvanted with Amphigen�, swine (including pregnant sows and gilts) 3 weeks and older. Meat withdrawal: 21 days.
RESPISURE�/ER BAC PLUS�
Zoetis
Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin
For use in swine only
PRODUCT DESCRIPTION: RespiSure/ER Bac Plus is for vaccination of healthy swine, including pregnant sows and gilts, 3 weeks of age or older as an aid in preventing erysipelas caused by Erysipelothrix rhusiopathiae for a period of 20 weeks and respiratory disease caused by Mycoplasma hyopneumoniae. RespiSure/ER Bac Plus is a liquid preparation of a chemically inactivated whole cell culture of M. hyopneumoniae and a serum-free, clarified E. rhusiopathiae culture, plus Amphigen�, a unique oil-in-water adjuvant to enhance the immune response.
DISEASE DESCRIPTION: Mycoplasmal pneumonia of swine (MPS), or enzootic pneumonia, is a widespread, chronic disease characterized by coughing, growth retardation, and reduced feed efficiency. The etiologic agent is M. hyopneumoniae; however, the naturally occurring disease often results from a combination of bacterial and mycoplasmal infections.
MPS causes considerable economic loss in all areas where swine are raised. Surveys conducted at various locations throughout the world indicate that lesions typical of those seen with MPS occur in 30%-80% of slaughter-weight swine. Because mycoplasmal lesions may resolve before hogs reach slaughter weight, the actual incidence may be higher. The prevalence of M. hyopneumoniae infection in chronic swine pneumonia has been reported to range from 25%1-93%.2 Pigs of all ages are susceptible to MPS, but the disease is most common in growing and finishing swine. Current evidence indicates that M. hyopneumoniae is transmitted by aerosol or direct contact with respiratory tract secretions from infected swine. Transmission from sow to pig during lactation is possible.3 Once established, MPS occurs year after year in infected herds, varying in severity with such environmental factors as season, ventilation, and concentration of swine.
Clinical signs of MPS include a chronic, nonproductive cough continuing for weeks or months, unthrifty appearance, and retarded growth, even though the appetites of infected swine remain normal. Stunting may occur, resulting in considerable variation in size among affected pigs. Death loss associated with secondary bacterial infection and stress may occur.
SAFETY AND EFFICACY: The safety of RespiSure/ER Bac Plus in pigs was demonstrated in 3 field safety studies conducted in 3 different geographic locations. Nine hundred and six pigs were vaccinated at approximately 3 and 6 weeks of age. No injection site reactions or serious systemic reactions were observed following vaccination.
DIRECTIONS:
1. General Directions: Vaccination of all pigs on the premises is recommended to enhance herd immunity. Shake well. Aseptically administer 2 mL intramuscularly.
2. Primary Vaccination: Healthy swine 3 weeks of age or older should receive two 2-mL doses administered approximately 3 weeks apart. In young pigs, vaccinate after maternally derived antibodies to E. rhusiopathiae have declined.
3. Revaccination: Semiannual revaccination with a single dose is recommended.
4. Good animal husbandry and herd health management practices should be employed.
PRECAUTIONS:
1. Store at 2�-7�C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine.
4. Do not vaccinate within 21 days before slaughter.
5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
6. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
